Skip to main content

Moleculin Biotech, Inc.

MBRX
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001659617

In the last 90 days, Moleculin Biotech, Inc. insiders filed 3 open-market purchases and 0 sales; 18 institutions reported holding it in 13F filings for Q2 2026, worth $518.5K in total; no superinvestor holds it.

Q4 2023 vs. Q3 2023

How the institutions holding Moleculin Biotech, Inc. changed between Q3 2023 and Q4 2023.

All holders in Q4 2023All holders in Q3 2023

13F holders of MBRX: Q3 2023 compared with Q4 2023
MeasureQ3 2023Q4 2023Change
Holders2224+2
Shares2.15M5.18M+3.03M (+140.8%)
Value$925.1K$4.44M+$3.51M (+379.8%)

New holders (7)

Institutions that held Moleculin Biotech, Inc. at the end of Q4 2023 but not at the end of Q3 2023.

Institutions new to MBRX in Q4 2023
InstitutionSharesValue% of portfolio
Armistice Capital, LLC3,207,417$2.75M0.07%
Citadel Advisors LLC64,652$55.5K0.00%
Atticus Wealth Management, LLC50,001$42.9K0.02%
Sandy Spring Bank1,333$1.15K0.00%
CVA Family Office, LLC500$4290.00%
GWM Advisors LLC2$20.00%
Hazlett, Burt & Watson, Inc.67$00.00%

Sold out (5)

Institutions that held Moleculin Biotech, Inc. at the end of Q3 2023 and filed for Q4 2023 without it.

Institutions that sold out of MBRX in Q4 2023
InstitutionShares, Q3 2023Value, Q3 2023
Sio Capital Management, LLC271,230$116.0K
Millennium Management LLC30,493$13.0K
UBS Group AG200$85
FMR LLC2$1
NBC Securities, Inc.200$0